SCHEMBL6964349

SCHEMBL6964349

O=C1C(=Cc2c[nH]c3ccccc23)Oc2cc(O)ccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.70
MTOR P42345 4/20 0.70
HASPIN Q8TF76 1/20 0.69
MAOA P21397 3/20 0.64
MAOB P27338 2/20 0.64
CISD1 Q9NZ45 1/20 0.64
TYR P14679 4/20 0.60
MIF P14174 1/20 0.57
INPPL1 O15357 1/20 0.57
PIM1 P11309 2/20 0.52
PIK3CG P48736 2/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
RECQL P46063 2/20 0.51
POLB P06746 1/20 0.51
RAB9A P51151 1/20 0.51
KDM4E B2RXH2 1/20 0.51
PSMD14 O00487 1/20 0.51
AURKA O14965 1/20 0.51
NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29516892 1.00 PIK3CA (0.70) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL14735399 1.00 PIK3CA (0.70) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL29516830 1.00 PIK3CA (0.70) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL1429246 0.85 HASPIN (0.60) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL4324811 0.85 PIK3CA (0.72) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL4325371 0.85 HASPIN (0.60) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL1428596 0.85 PIK3CA (0.72) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL19462967 0.85 MAOB (0.63) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL4330364 0.85 MAOB (0.63) PIK3CAMTORHASPINMAOAMAOB
SCHEMBL1428628 0.85 MAOB (0.63) PIK3CAMTORHASPINMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2565192-B9 ANTICANCER AGENT UNIV TOKYO (JP) 2015-11-25 EP disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 US disclosed
EP-2565192-B1 ANTICANCER AGENT UNIV TOKYO (JP) 2015-08-12 EP disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 US disclosed
EP-2565192-A1 ANTICANCER AGENT The University of Tokyo (JP) 2013-03-06 EP disclosed
EP-0902022-B1 NOVEL BENZOFURANONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME DAIICHI SEIYAKU CO (JP) 2003-07-30 EP disclosed
US-6143779-A Benzofuranone derivatives and a method for producing them SNOW BRAND MILK PRODUCTS CO., LTD. (JP) 2000-11-07 US disclosed
EP-0902022-A1 NOVEL BENZOFURANONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SNOW BRAND MILK PRODUCTS CO., LTD. (JP) 1999-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102776-A1 ANTICANCER AGENT PIM1, PIM3, PIM2 PIK3CA 942/4885MTOR 103/4885HASPIN 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.